Search results
Results from the WOW.Com Content Network
meta. -Chlorophenylpiperazine. meta-Chlorophenylpiperazine (mCPP) is a psychoactive drug of the phenylpiperazine class. It was initially developed in the late-1970s and used in scientific research before being sold as a designer drug in the mid-2000s. [4][5] It has been detected in pills touted as legal alternatives to illicit stimulants in New ...
Generic Product Identifier. The Generic Product Identifier (GPI) is a 14-character hierarchical classification system created by Wolters Kluwer's Medi-Span that identifies drugs from their primary therapeutic use down to the unique interchangeable product regardless of manufacturer or package size. The code consists of seven subsets, each ...
Hydrochlorothiazide. Hydrochlorothiazide, sold under the brand name Hydrodiuril among others, is a diuretic medication used to treat hypertension and swelling due to fluid build-up. [4] Other uses include treating diabetes insipidus and renal tubular acidosis and to decrease the risk of kidney stones in those with a high calcium level in the ...
Susan Spratt, an endocrinologist and the senior medical director for the Population Health Management Office at Duke Health, went so far as to compare it to a "miracle pill," NBC News reported.
Zolpidem is a nonbenzodiazepine, or Z-drug, which acts as a sedative and hypnotic. [11][20] Zolpidem is a GABA A receptor agonist of the imidazopyridine class. [11] It works by increasing GABA effects in the central nervous system by binding to GABA A receptors at the same location as benzodiazepines. [11]
Dexpramipexole is a first-in-class oral investigational medicine that lowers blood and tissue eosinophils before they can cause damage in the target organ. Dexpramipexole is being developed by Areteia Therapeutics and has the potential to be the first oral treatment ever approved for eosinophilic asthma.
Apomorphine, sold under the brand name Apokyn among others, is a type of aporphine having activity as a non-selective dopamine agonist which activates both D 2-like and, to a much lesser extent, D 1-like receptors. [2]
For the first twelve weeks of use, it is advised to take the ormeloxifene pill twice per week. [6] From the thirteenth week on, it is taken once per week. [6] [7] The consensus is that backup protection in the first month is a cautious but sensible choice. A standard dose is 30 mg weekly, but 60 mg loading doses can reduce pregnancy rates by 38 ...